Objective To compare the efficacy of the erlotinib versus gefitinib in the first-line treatment of
patients with advanced EGFR mutation-positive NSCLC. Methods Fifty patients with …

Background and objective Targeted therapy in non-small cell lung cancer (NSCLC) had
become a research hotspot. Both of gefitinib and erlotinib had already been recommended …

19072 Background: Non-small cell lung cancer (NSCLC) patients with epidermal growth
factor receptor (EGFR) mutation show excellent response to gefitinib, but eventually develop …

Backgrounds Efficacy of gefitinib therapy strongly depends on epidermal growth factor
receptor (EGFR)-mutation status in Asian patients with non-small cell lung cancer. Recently …

Background Several clinical trials showed that erlotinib was effective after the failure of
gefitinib in advanced non-small cell lung cancer (NSCLC). The aim of this study was to …

Purpose This study was designed to evaluate the efficacy and toxicity of erlotinib in patients
with advanced non–small-cell lung cancer (NSCLC) who experienced disease progression …

Purpose The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs)
gefitinib and erlotinib have shown dramatic response rate (RR) and significant prolongation …

Purpose Whether bevacizumab enhances the effect of the epidermal growth factor receptor
(EGFR) inhibitor gefitinib on EGFR mutant non–small cell lung cancers (NSCLCs) remains …

Methods A retrospective cohort study of 88 NSCLC patients with EGFR mutation positive
treated with gefitinib (n= 59), erlotinib (n= 22), and afatinib (n= 7) was performed in national …

Introduction The epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib
is associated with survival benefits in patients with EGFR mutation-positive non-small-cell …